66.78
price up icon2.87%   1.86
pre-market  Pre-mercato:  68.67   1.89   +2.83%
loading
Precedente Chiudi:
$64.92
Aprire:
$65.52
Volume 24 ore:
8.96M
Relative Volume:
0.92
Capitalizzazione di mercato:
$226.39B
Reddito:
$43.59B
Utile/perdita netta:
$15.04B
Rapporto P/E:
19.78
EPS:
3.3766
Flusso di cassa netto:
$10.74B
1 W Prestazione:
-0.65%
1M Prestazione:
-9.48%
6M Prestazione:
-17.12%
1 anno Prestazione:
-49.86%
Intervallo 1D:
Value
$65.45
$66.97
Intervallo di 1 settimana:
Value
$64.12
$68.04
Portata 52W:
Value
$57.00
$139.74

Novo Nordisk Adr Stock (NVO) Company Profile

Name
Nome
Novo Nordisk Adr
Name
Telefono
-
Name
Indirizzo
-
Name
Dipendente
77,406
Name
Cinguettio
@novonordisk
Name
Prossima data di guadagno
2024-12-06
Name
Ultimi documenti SEC
Name
NVO's Discussions on Twitter

Confronta NVO con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
66.78 298.68B 43.59B 15.04B 10.74B 3.3766
Drug Manufacturers - General icon
LLY
Lilly Eli Co
776.44 692.83B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
167.93 373.35B 90.63B 22.66B 18.57B 9.35
Drug Manufacturers - General icon
ABBV
Abbvie Inc
187.11 329.24B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
116.83 231.66B 55.19B 13.65B 16.81B 6.86

Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-04-17 Downgrade BMO Capital Markets Outperform → Market Perform
2025-03-13 Aggiornamento Kepler Hold → Buy
2025-03-03 Downgrade Stifel Buy → Hold
2025-02-12 Iniziato Morgan Stanley Equal-Weight
2025-01-06 Aggiornamento Bernstein Underperform → Mkt Perform
2024-05-30 Iniziato Goldman Buy
2024-04-12 Iniziato BMO Capital Markets Outperform
2024-01-23 Iniziato Morgan Stanley Overweight
2024-01-16 Ripresa UBS Neutral
2023-12-01 Iniziato Cantor Fitzgerald Overweight
2023-10-02 Iniziato Argus Buy
2023-07-14 Iniziato HSBC Securities Buy
2022-07-15 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2022-06-28 Downgrade UBS Neutral → Sell
2022-06-27 Aggiornamento Exane BNP Paribas Underperform → Neutral
2022-06-07 Aggiornamento JP Morgan Neutral → Overweight
2022-05-31 Aggiornamento Guggenheim Neutral → Buy
2022-04-25 Aggiornamento Cowen Market Perform → Outperform
2022-04-12 Aggiornamento Morgan Stanley Underweight → Equal-Weight
2022-03-16 Aggiornamento Deutsche Bank Hold → Buy
2022-01-25 Downgrade Liberum Hold → Sell
2021-12-20 Downgrade JP Morgan Overweight → Neutral
2021-12-17 Downgrade Deutsche Bank Buy → Hold
2021-01-20 Downgrade Credit Suisse Outperform → Neutral
2021-01-15 Iniziato Deutsche Bank Buy
2020-09-29 Iniziato Berenberg Hold
2020-07-06 Downgrade BofA Securities Buy → Neutral
2020-05-11 Downgrade UBS Buy → Neutral
2020-05-04 Iniziato Cowen Market Perform
2020-03-16 Aggiornamento BofA/Merrill Neutral → Buy
2020-01-03 Downgrade Guggenheim Buy → Neutral
2019-11-18 Aggiornamento Barclays Equal Weight → Overweight
2019-09-17 Aggiornamento Citigroup Neutral → Buy
2019-08-30 Downgrade Jefferies Hold → Underperform
2019-06-20 Downgrade Deutsche Bank Buy → Hold
2019-06-11 Aggiornamento Barclays Underweight → Equal Weight
2019-04-29 Aggiornamento Credit Suisse Neutral → Outperform
2019-01-29 Iniziato Exane BNP Paribas Outperform
2018-12-11 Ripresa Jefferies Hold
2018-10-09 Iniziato Guggenheim Buy
2017-12-29 Aggiornamento JP Morgan Underweight → Neutral
2017-12-06 Aggiornamento BofA/Merrill Neutral → Buy
2017-12-01 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2017-09-25 Downgrade Exane BNP Paribas Outperform → Neutral
2017-09-06 Aggiornamento BofA/Merrill Underperform → Neutral
Mostra tutto

Novo Nordisk Adr Borsa (NVO) Ultime notizie

pulisher
Jul 21, 2025

Hims & Hers Health, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Wolf Haldenstein Before August 25, 2025 to Discuss Your Rights - GlobeNewswire Inc.

Jul 21, 2025
pulisher
Jul 16, 2025

HIMS & HERS HEALTH SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Hims & Hers Health, Inc. - GlobeNewswire Inc.

Jul 16, 2025
pulisher
Jul 16, 2025

Novo Nordisk’s GLP-1 Reign Faces New Pressures In 2025 - Finimize

Jul 16, 2025
pulisher
Jul 15, 2025

HIMS & HERS HEALTH SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Hims & Hers Health, Inc. - GlobeNewswire Inc.

Jul 15, 2025
pulisher
Jul 15, 2025

NVO’s 2025 Market Dance: Down -51.70% – Time to Invest? - investchronicle.com

Jul 15, 2025
pulisher
Jun 24, 2025

Novo Nordisk's Cardiometabolic Foundation Supports Wide Moat - Morningstar

Jun 24, 2025
pulisher
Jun 22, 2025

Novo Nordisk: Navigating Challenges to Dominate Diabetes and Obesity Therapies - AInvest

Jun 22, 2025
pulisher
Jun 19, 2025

The Skinny On Novo Nordisk: This Slimmed-Down Stock May Be Worth A... Shot - Finimize

Jun 19, 2025
pulisher
Jun 17, 2025

NVO’s Stock Woes: Down -31.04% in 6 Months, Down -31.04% in Just 5 Days - investchronicle.com

Jun 17, 2025
pulisher
Jun 16, 2025

European Stocks Shine As ADRs Climb Higher - Finimize

Jun 16, 2025
pulisher
Jun 13, 2025

After ousting CEO, Novo Nordisk reclaims crown as largest European company - MSN

Jun 13, 2025
pulisher
Jun 10, 2025

Why Novo Nordisk Stock Just Popped - Barchart.com

Jun 10, 2025
pulisher
May 31, 2025

European ADRs Show Strength With Genfit And Novo Nordisk Leading Gains - Finimize

May 31, 2025
pulisher
May 30, 2025

European ADRs Show Resilience In US Market - Finimize

May 30, 2025
pulisher
May 19, 2025

Novo Nordisk Faces Obesity Competition, but Innovation Still Warrants a Wide Moat - Morningstar

May 19, 2025
pulisher
May 19, 2025

Bio/Pharmaceutical Outsourcing Report, March 2025 Edition - GlobeNewswire Inc.

May 19, 2025
pulisher
May 16, 2025

European ADRs Dip As Pharma And Tech Stocks See Mixed Results - Finimize

May 16, 2025
pulisher
May 13, 2025

What Did We Find About Insider Trading At Novo Nordisk ADR (NYSE: NVO)? - Stocksregister

May 13, 2025
pulisher
May 10, 2025

European Stocks Show Mixed Results With Novo Nordisk Leading Gains - Finimize

May 10, 2025
pulisher
May 09, 2025

Novo Nordisk Q1 Earnings Match Estimates, Revenues Rise Y/Y, Stock Up - MSN

May 09, 2025
pulisher
May 08, 2025

Novo Nordisk ADR earnings beat by $5.64, revenue topped estimates - Investing.com Nigeria

May 08, 2025
pulisher
May 07, 2025

Novo Nordisk Earnings: Compounders Pressured Q1 Wegovy Sales - Morningstar

May 07, 2025
pulisher
May 07, 2025

Novo Nordisk Earnings: Compounders Pressured Q1 Wegovy Sales, but Strategy Should Preserve Growth - Morningstar

May 07, 2025
pulisher
May 07, 2025

European ADRs See Mixed Results With Modest Gains - Finimize

May 07, 2025
pulisher
May 07, 2025

Novo Nordisk expects U.S. sales of Wegovy weight-loss drug to recover soon, CEO says - The Globe and Mail

May 07, 2025
pulisher
May 07, 2025

Market news - investments.halifax.co.uk

May 07, 2025

Novo Nordisk Adr Azioni (NVO) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
drug_manufacturers_general NVS
$116.83
price up icon 2.36%
drug_manufacturers_general MRK
$81.61
price up icon 2.90%
$305.69
price up icon 3.32%
drug_manufacturers_general PFE
$25.14
price up icon 3.63%
$110.17
price up icon 1.75%
Capitalizzazione:     |  Volume (24 ore):